Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 11/20 | 0.41 |
| ▸ | NOS3 | P29474 | 10/20 | 0.41 |
| ▸ | NOS2 | P35228 | 7/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CBX7 | O95931 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6583013 | 0.95 | CBX7 (0.41) | NOS1NOS3NOS2GAACBX7 | |
| SCHEMBL6583956 | 0.90 | NOS1 (0.48) | NOS1NOS3NOS2 | |
| SCHEMBL957006 | 0.87 | NOS3 (0.48) | NOS1NOS3NOS2KDM4EALDH1A1 | |
| SCHEMBL4290837 | 0.87 | LMNA (0.41) | NOS1NOS3NOS2GAACBX7 | |
| SCHEMBL222427 | 0.82 | NOS3 (0.48) | NOS1NOS3NOS2KDM4ESMN1; SMN2 | |
| SCHEMBL221914 | 0.79 | NOS3 (0.63) | NOS1NOS3NOS2KDM4EALDH1A1 | |
| SCHEMBL6585074 | 0.76 | ACACA (0.50) | NOS1NOS3KDM4E | |
| SCHEMBL4282766 | 0.76 | NOS1 (0.53) | NOS1NOS3NOS2GAAKDM4E | |
| SCHEMBL221387 | 0.75 | NOS1 (0.46) | NOS1NOS3NOS2 | |
| SCHEMBL6583088 | 0.75 | NOS1 (0.40) | NOS1NOS3NOS2CBX7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150175645-A1 | NICOTINAMIDE RIBOSIDE AND ANALOGUES THEREOF | GLAXOSMITHKLINE LLC (US) | 2015-06-25 | — | — | US | disclosed |
| US-20120197013-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-8178536-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20120022254-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-8093401-B2 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8088928-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8044198-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20110130387-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110009496-A1 | RESVERATROL FORMULATIONS | SIRTRIS PHARMACEUTICAS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-7855289-B2 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-20090163476-A1 | N-Phenyl Benzamide Derivatives as Sirtuin Modulators | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090099170-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-7345178-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070043050-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRTIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20060276393-A1 | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130387-A1 | SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | NOS1 357/4885NOS3 349/4885NOS2 422/4885 |
| US-20090099170-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | NOS1 357/4885NOS3 349/4885NOS2 422/4885 |
| US-20110009496-A1 | RESVERATROL FORMULATIONS | SIRT1, SIRT5, SIRT2 | NOS1 728/4885NOS3 1835/4885NOS2 1029/4885 |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRT2, SIRT1, SIRT3 | NOS1 297/4885NOS3 462/4885NOS2 198/4885 |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRT1, SIRT3, SIRT2 | NOS1 737/4885NOS3 940/4885NOS2 870/4885 |
| US-20150175645-A1 | NICOTINAMIDE RIBOSIDE AND ANALOGUES THEREOF | SIRT1, NAMPT, SIRT2 | NOS1 156/4885NOS3 243/4885NOS2 217/4885 |
| US-20090163476-A1 | N-Phenyl Benzamide Derivatives as Sirtuin Modulators | SIRT1, SIRT3, SIRT2 | NOS1 280/4885NOS3 291/4885NOS2 225/4885 |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRT2, SIRT1, SIRT3 | NOS1 317/4885NOS3 330/4885NOS2 171/4885 |
| US-20120022254-A1 | SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | NOS1 357/4885NOS3 349/4885NOS2 422/4885 |
| US-20120197013-A1 | SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | NOS1 357/4885NOS3 349/4885NOS2 422/4885 |
| US-20070043050-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | NOS1 624/4885NOS3 779/4885NOS2 687/4885 |
| US-20060276393-A1 | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders | SIRT2, SIRT1, SIRT3 | NOS1 457/4885NOS3 422/4885NOS2 136/4885 |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | NOS1 624/4885NOS3 779/4885NOS2 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.